Key points are not available for this paper at this time.
"Standard heart failure medication in cardiac transthyretin amyloidosis: useful or harmful?." Amyloid, 24(sup1), pp. 132–133
Share your take
Add a clinician perspective alongside expert commentary.
Siepen et al. (2017) studied this question.